Misbranding

Par Pharma to Pay $45M for Health Care Fraud, Whistleblowers to Get $4.4M
March 6, 2013
New Jersey-based Par Pharmaceutical Companies Inc. pleaded guilty in federal court yesterday and agreed to pay $45 million to resolve its criminal and civil liability in the company’s promotion of its prescription drug Megace® ES for uses not approved as safe and effective by the Food and Drug Administration (FDA) and not covered by federal health care programs, the...
False Claims / Whistleblowers
False Claims Act, FDA, Fraud, Fraud Against Government, Misbranding, Pharmaceuticals, Whistleblowers
Read More